InnoCare Pharma (9969) Q1 2026 earnings summary

Executive summary

• Total revenue increased by 38.7% year-over-year in Q1 2026, reaching RMB 529 million, driven by a 44.54% rise in drug sales and milestone payments from business development and licensing agreements.

• Net profit surged to RMB 102 million, up over 607% year-over-year, supported by robust sales, milestone payments, and improved cost efficiency.

• Strong cash position of RMB 7.9 billion as of March 31, 2026, providing flexibility for R&D and pipeline investment.

Financial highlights

• Drug sales reached RMB 450 million in Q1 2026, up from RMB 312 million in Q1 2025.

• Operating revenue was RMB 528.6 million, up 38.65% year-over-year.

• R&D expenses increased by 10.4% year-over-year to RMB 229 million, reflecting strategic investment in clinical trials and technology platforms.

• Basic and diluted EPS: RMB 0.06, up 500% year-over-year.

• Net cash flows from operating activities: RMB 4.2 million, down 92.53% year-over-year due to increased production, R&D, and tax payments.

Outlook and guidance

• Multiple near-term catalysts expected, including NDA submissions for ITP and pediatric NTRK tumors, and data readouts for key Phase 3 trials in oncology and autoimmune diseases.

• Accelerated global clinical development and expansion into new indications and geographies.

• Management expects to maintain high-quality growth, leveraging a mature commercialization system and robust R&D pipeline.

• Sufficient cash reserves will support accelerated development of pipeline projects.